Every immunization donor eventually has to answer an uncomfortable question: when does a country stop needing help paying for vaccines? For Gavi, the Vaccine Alliance, the answer is not a single cutoff date but a multi-year policy called graduation, or transition. It determines when a government takes over 100% of its own vaccine bill, and the design of that policy — not just the moment of eligibility loss — shapes whether a national immunization program keeps its coverage gains or slides backward. Understanding Gavi graduation policy matters for anyone tracking how developing nations move from donor dependency toward self-financed health systems.
How the eligibility threshold works
Gavi support is tied to a single economic indicator: Gross National Income (GNI) per capita, using World Bank data. Since January 2011, Gavi has set an eligibility threshold that is adjusted annually to hold constant in real terms; for 2026, a country qualifies for support if its most recent GNI per capita is at or below US$2,300. Cross that line and a government does not lose support overnight — it enters a structured, government-led transition process instead.
The four phases of transition
Gavi’s model links a country’s co-financing share directly to its income growth, moving through defined stages:
- Initial self-financing phase. The government pays a modest share of vaccine costs from the outset, establishing the habit of budgeting for immunization before any transition is triggered.
- Preparatory transition phase. Once a country nears the threshold, its co-financing share rises by 15 percentage points per year after an initial grace year, giving finance ministries a predictable ramp rather than a shock.
- Accelerated transition phase. When GNI per capita exceeds the threshold and co-financing has reached at least 35%, an eight-year clock starts. Co-financing climbs to 100% of vaccine costs by the end of it, though the country can still apply for support that strengthens routine immunization or improves equity.
- Fully self-financing. After the eight years, the country funds its entire vaccine program and can no longer draw new financial support from Gavi for existing vaccines.
Before a country is formally moved along this path, a multi-partner Transition Assessment identifies programmatic and financial bottlenecks, and the results feed a government-owned Transition Plan. Gavi also builds in a safety valve: if a formerly eligible country’s GNI per capita later falls back below the threshold, it can regain Gavi-eligible status and be reclassified into the appropriate phase.
India: transition paired with a soft landing
India began transitioning away from Gavi funding in 2017, with full self-financing targeted for 2021. Between 2016 and 2021, Gavi provided up to US$500 million to support the country’s immunization program — support that was projected to help prevent several hundred thousand deaths by accelerating the rollout of vaccines against pneumonia, severe diarrhea, measles-rubella, and HPV. India’s number of "zero-dose" children (those who have received no routine vaccinations at all) fell from 6.8 million in 2000 to 1.6 million in 2019, before the pandemic pushed it back up to 2.7 million in 2021.
What distinguishes India’s case is what came after graduation. India became fully self-financing in 2022, yet Gavi did not simply exit: a new three-year partnership announced in February 2023 committed US$250 million toward reaching "zero-dose" children, strengthening health systems, and introducing HPV and typhoid conjugate vaccines. India has also reversed roles, pledging US$15 million to Gavi over five years starting in 2020 and now supplying over 60% of the vaccine doses Gavi procures worldwide — a graduated recipient becoming both funder and manufacturer.
Vietnam: the harder edge of the same policy
Vietnam was one of 19 countries slated to transition out of Gavi support between 2016 and 2020. In 2017, the Prime Minister approved an immunization budget guaranteeing increased domestic financing for vaccines and cold-chain infrastructure through 2020, and the country built a genuinely strong track record on coverage and government commitment going into the transition.
The strain showed up later, on the financing-architecture side rather than the policy-design side. As international aid wound down, a 2023 shift of funding responsibility onto provincial governments led to vaccine shortages and a documented decline in childhood immunization rates in parts of the country. Vietnam has continued to seek Gavi’s involvement since — not as core financing, but for policy development, capacity building, and support introducing newer vaccines such as pneumococcal conjugate and HPV vaccines, and Gavi has signaled it remains ready to help on that narrower footing.
What the comparison says about policy design
| Factor | India | Vietnam |
|---|---|---|
| Transition trigger year | 2017 | 2016–2020 cohort |
| Domestic financing decision | National-level budget commitment sustained post-graduation | Financing devolved to provincial governments in 2023 |
| Post-graduation Gavi role | New funded partnership (2023) plus India as a Gavi donor | Technical support only, no new core financing |
| Reported outcome | Continued coverage gains, pandemic-era dip recovering | Localized vaccine shortages and coverage decline reported |
The difference was not the transition timeline — both countries followed the same broad Gavi structure. It was what each government did with the co-financing ramp once it started: whether the national budget line absorbed the rising share smoothly, and whether that responsibility stayed centralized or fragmented into subnational budgets that vaccines have to compete against for funding every cycle.
Conclusion
Gavi graduation policy is designed to be gradual precisely because abrupt donor exits have historically been where immunization programs break. The eight-year accelerated phase, the re-eligibility safety valve, and the option to keep applying for equity-focused support all exist to prevent a funding cliff. But the policy can only manage the glide path — it cannot guarantee that a finance ministry keeps vaccines fully funded once co-financing hits 100%. For health policy strategists in the developing nations closest to their own threshold, the lesson from these two cases is less about hitting the trigger and more about whether domestic financing is structured to hold once Gavi graduation actually arrives.